logo
Select company
Select metric
2.16Cash Ratio
VS
Market
83
Sector
66
Industry
54
History
50
$ 8.3Close
$ 6.41 - $ 16.8 52-Week Range
Ticker Information

Ticker

GYRE

Company Name

GYRE THERAPEUTICS INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

GYRE THERAPEUTICS INC - Cash Ratio Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

GYRE - Cash Ratio Historical data
DateCash and EquivalentsCash RatioCurrent Liabilities
6/30/2025$ 36.49M2.16$ 16.92M
3/31/2025$ 15.04M0.79$ 18.99M
12/31/2024$ 11.81M0.61$ 19.52M
9/30/2024$ 15.87M1.08$ 14.72M
6/30/2024$ 16.1M1.03$ 15.57M
3/31/2024$ 29.79M1.53$ 19.49M
12/31/2023$ 33.51M1.67$ 20.05M
9/30/2023$ 2.23M1.25$ 1.78M
6/30/2023$ 6.92M2.48$ 2.79M
3/31/2023$ 8.1M1.18$ 6.84M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • GYRE THERAPEUTICS INC's latest trailing twelve months (TTM) Cash Ratio stands at 1.48.
  • Over the past 5 years, GYRE THERAPEUTICS INC's average Cash Ratio has been 3.48.
  • The median Cash Ratio for GYRE THERAPEUTICS INC during this period was 1.69
  • GYRE THERAPEUTICS INC reached its highest Cash Ratio over the past 5 years at 17.49.
  • The lowest Cash Ratio recorded by GYRE THERAPEUTICS INC in the same timeframe 0.61

GYRE THERAPEUTICS INC's Cash Ratio vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

Cash Ratio Benchmarks
CompanyCash Ratio
PHAT : PHATHOM PHARMACEUTICALS INC 1.66NAGE : NIAGEN BIOSCIENCE INC 2.71ANAB : ANAPTYSBIO INC 1.25TBPH : THERAVANCE BIOPHARMA INC 5.18URGN : UROGEN PHARMA LTD 1.98CRMD : CORMEDIX INC 5.02NRIX : NURIX THERAPEUTICS INC 0.96ZVRA : ZEVRA THERAPEUTICS INC 1.65KURA : KURA ONCOLOGY INC 0.76SAGE : SAGE THERAPEUTICS INC 1.54

Definition of Cash Ratio

[Calculation] The Cash Ratio is a liquidity indicator that describes a company's ability to meet short-term obligations with cash and cash equivalents. Calculated by dividing cash and cash equivalents [CashnEq] by current liabilities [LiabilitiesC].
CashnEq / LiabilitesC
(=) Cash Ratio
Cash Ratio for GYRE THERAPEUTICS INC is calculated as follows: CashnEq [ $ 24.92M ] / LiabilitesC [ $ 16.82M ]
(=) Cash Ratio [ 1.48 ]

GYRE - Cash Ratio, Last 5 years

0.61

Minimum

Dec 31, 2024

17.49

Maximum

Jun 30, 2022

3.48

Average

1.69

Median

Cash Ratio Benchmark Analysis

The chart above depicts the distribution of Cash Ratio for companies in the Total Stock Market. The average Cash Ratio of the companies is 0.62 with a standard deviation of 0.63.
The following table provides additional summary stats:
Cash Ratio in the Market:
filtered constituents3.13K
min0
max2.69
average0.62
median0.39
std0.63